Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Otitis Media Guidance To Offer “Flexible Approach” To Trial Design

Executive Summary

FDA's otitis media guidance will offer a "flexible approach" to designing trials for anti-infective drugs being developed for the condition, the agency said

You may also be interested in...

Otitis Media Draft Guidance May Address Tympanocentesis Use, Study Size

The size of trials for acute otitis media could depend on whether tympanocentesis is used in the design, FDA Anti-Infective Drugs Advisory Committee member James Leggett, MD, Oregon Sciences University, said

Pfizer Zithromax Otitis Media Single-Dose Needs PK Studies, Cmte. Says

Pfizer Zithromax one-day and three-day dosing regimens need more pharmacokinetic studies in children with acute otitis media, FDA's Anti-Infective Drugs Advisory Committee recommended Nov. 7

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts